NCT01493440

Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: An Sinh Hospital · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Detailed description

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

Conditions

• Repeated Implantation Failure

Interventions

Type	Name	Description
DRUG	atosiban	Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.

Timeline

• Start date: 2011-03-01
• Primary completion: 2011-08-01
• Completion: 2011-09-01
• First posted: 2011-12-16
• Last updated: 2011-12-20

Locations

1 site across 1 country: Vietnam